Benchmark Maintains Speculative Buy on Biolase, Lowers Price Target to $0.4
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Bruce Jackson has maintained a Speculative Buy rating on Biolase (NASDAQ:BIOL) but has significantly lowered the price target from $2.5 to $0.4.
March 22, 2024 | 5:42 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Benchmark analyst Bruce Jackson maintains a Speculative Buy on Biolase but lowers the price target from $2.5 to $0.4.
The significant reduction in the price target from $2.5 to $0.4 by a Benchmark analyst, while maintaining a Speculative Buy rating, suggests a negative outlook on the stock's short-term price potential. This could lead to a decrease in investor confidence and potentially lower stock prices in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100